Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • 2022
  • Article
  • Review of Financial Studies

Missing Novelty in Drug Development

By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
  • Format:Print
ShareBar

Abstract

We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to obtain FDA approval but are based on more valuable patents. Consistent with a simple model of costly external finance, we show that a positive shock to firms’ net worth leads firms to develop more novel drugs. This suggests that even large firms may behave as though they are risk averse, reducing their willingness to investment in potentially valuable radical innovation.

Keywords

Drug Development; Risk Aversion; Research and Development; Innovation and Invention; Investment; Pharmaceutical Industry

Citation

Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou. "Missing Novelty in Drug Development." Review of Financial Studies 35, no. 2 (February 2022): 636–679.

Supplemental Information

Data Overview
Data Overview
  • SSRN
  • Find it at Harvard
  • Register to Read

About The Author

Joshua Lev Krieger

Entrepreneurial Management
→More Publications

More from the Authors

    • February 2025
    • Faculty Research

    Fly, Fix, Fly at True Anomaly

    By: Joshua Lev Krieger, Jim Matheson, Fiona Murray and David Allen
    • January 2025
    • Faculty Research

    DMC Biotechnologies: Using Techno-Economic Modeling to Guide Production Strategy

    By: Joshua Lev Krieger, Chris Burk and Jim Matheson
    • January 2025
    • Faculty Research

    Launching Tough Tech Ventures

    By: Joshua Lev Krieger and Jim Matheson
More from the Authors
  • Fly, Fix, Fly at True Anomaly By: Joshua Lev Krieger, Jim Matheson, Fiona Murray and David Allen
  • DMC Biotechnologies: Using Techno-Economic Modeling to Guide Production Strategy By: Joshua Lev Krieger, Chris Burk and Jim Matheson
  • Launching Tough Tech Ventures By: Joshua Lev Krieger and Jim Matheson
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.